The combination of the IGF-IR inhibitor linsitinib and fulvestrant is more effective than the single agent in HR+ BC cells,154 and treatment with the IGF-IR monoclonal antibody is capable of overcoming resistance to hormone deprivation or anti-estrogen therapy.155. This evidence concerns the gene IGF1R and breast cancer.